On April 4, 2017 Nativis, Inc. (Nativis), a clinical-stage life science bio-electronic company developing non-invasive, safe and highly effective treatments for cancers and other serious diseases, reported that the company has entered into an exclusive licensing agreement for the development and commercialization of Nativis’ proprietary ultra-low Radio Frequency Energy (ulRFE) technology for the potential treatment of Glioblastoma Multiforme (GBM) in the Japanese market, with Teijin Limited (Teijin), a comprehensive Japanese company expanding businesses in high-performance materials, pharmaceuticals, home healthcare, product converting and information technology (Press release, Nativis, APR 4, 2017, View Source [SID1234518476]). Schedule your 30 min Free 1stOncology Demo! Under the terms of the agreement, Teijin will receive an exclusive license to the Nativis Voyager System for the indication of GBM in Japan. Nativis will receive an undisclosed upfront payment, payments based on the achievement of specific regulatory and commercial milestones, and royalties on the sales of the product in Japan. Teijin will sublicense its rights under the agreement to Teijin Pharma Limited (Teijin Pharma), Teijin’s wholly-owned subsidiary and the core company of Teijin Group’s healthcare business, under which Teijin Pharma will develop and commercialize the licensed technology in Japan.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Nativis and Teijin also anticipate expansion of the scope of the alliance and will continue discussions for potential licensing opportunities of the Nativis ulRFE technology for other indications in Japan.
"We are very pleased to enter into this exclusive licensing agreement with Teijin for GBM; the company has a strong track record of successfully commercializing pharmaceuticals and medical devices in Japan. We believe that this partnership further validates our technology, while their investment in Nativis reinforces our belief in the broader potential of the Voyager platform. With their support, we look forward to further developing and refining the Voyager System for GBM, as well as additional indications in the future," commented Chris Rivera, President and Chief Executive Officer of Nativis. "This agreement also brings us one step closer to reaching our goal of becoming cash flow positive through strategic partnerships and licenses, and we are excited to work closely with Teijin to bring the Voyager System to market in Japan."O